Edwards Lifesciences (EW) Receivables (2009 - 2026)

Edwards Lifesciences has reported Receivables for 18 years, with the latest figure at $955.7 million in Q2 2026.

• On a quarterly basis, Receivables rose 5.88% year-over-year to $955.7 million in Q2 2026; TTM through Jun 2026 was $955.7 million, a 5.88% increase from a year earlier, with the FY2025 full-year figure at $912.1 million, up 25.39% from the prior year.
• Receivables was $955.7 million for Q2 2026 at Edwards Lifesciences, down from $973.0 million in the prior quarter.
• The five-year high for Receivables was $973.0 million in Q1 2026, with the low at $147.1 million in Q4 2024.
• Average Receivables over 5 years is $778.3 million, with a median of $814.2 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Receivables slumped 82.24% in 2024, then jumped 520.05% in 2025.
• Over 5 years, Receivables stood at $699.1 million in 2022, then climbed by 18.45% to $828.1 million in 2023, then plunged by 82.24% to $147.1 million in 2024, then surged by 520.05% to $912.1 million in 2025, then grew by 4.78% to $955.7 million in 2026.
• The last three Receivables figures came in at $955.7 million (Q2 2026), $973.0 million (Q1 2026), and $912.1 million (Q4 2025), per Business Quant data.